FLOWSION-A/S
Flowsion, the Denmark-based developer of automated continuous blood glucose control systems for intensive care medicine, today announced the CE (Conformité Européenne) Mark for its Glycostat™ automated glucose control system for intensive care medicine; GlycostatTM is the only blood glucose control system to be launched in the European Union (EU) with an algorithm which enables automated blood glucose control for patients in intensive care.
“With the CE mark we have reached an important milestone in our efforts to help patients and hospitals solving the important problem of glycemic control in the intensive care unit (ICU). For Flowsion this opens a globally relevant market opportunity,” said Hans Jorgen Pedersen, CEO of Flowsion. “Flowsion has already performed clinical studies with the system so we know already that Glycostat fulfils the demands of the intensive care units.”
“This kind of technology is really crucial for intensive care medicine, where patients’ lifes are threatened every day. Glucose control has proven to be very difficult to perform for the intensive care units in hospitals worldwide, and now getting a system that automatically helps performing blood glucose control will increase survival rate and lower treatment costs at the same time” said Hans Jorgen Pedersen. “We’ve carefully studied several technologies and designed a solution that is really elegant and simple to use, but that also delivers an enormous value for patients, doctors, nurses and hospitals.”
Flowsion has received support from The EU SME program which is designed to assist internationally oriented SMEs in implementing high-risk and high-potential innovation ideas. It aims at supporting projects with a European dimension that lead to major changes in how business is done.
About Flowsion
Flowsion is a European medical device company focusing exclusively on the needs of intensive care unit patients. Flowsion will launch new projects later on with other continuous measurement and control technologies for the ICU patients. More information can be found at: http://flowsion.dk
View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005203/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 13:00:00 CET | Press release
New data from the ongoing FLEX Study highlight the value of real-world evidence in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence c
Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 13:00:00 CET | Press release
First study to evaluate HER2DX in a randomized trial focused exclusively on older individuals (aged 70–80 years). HER2DX independently predicts long-term survival outcomes in patients treated with trastuzumab with or without chemotherapy. Findings support HER2DX as a tool to guide chemotherapy decisions and de-escalation strategies in older adults. REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 12:30:00 CET | Press release
Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submissionCompany now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026Cash position of $185.9 million as of September 30, 2025Conference call on November 4 at 8 am ET (1 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 mont
TELEO Capital Closes Oversubscribed TELEO Capital II at $350 Million Hard Cap4.11.2025 12:00:00 CET | Press release
TELEO Capital Management, LLC (“TELEO”), an operationally focused private equity firm focused on investing in lower middle market enterprise software companies, today announced the final close of TELEO Capital II (“Fund II”) at its hard cap of $350 million in Limited Partner capital commitments. Fund II was oversubscribed and attracted a diverse group of new and existing institutional investors. TELEO executes a time-tested strategy in the lower middle market, leveraging a large purpose-built team and repeatable process designed to deliver consistent, outsized returns. Fund II will continue TELEO’s focus on acquiring mission-critical software divisions of large corporations. TELEO is an ideal partner to large corporate sellers in need of a solution where speed and certainty to close, minimal post-closing distraction risk from shared services agreements, and a commitment to protecting customer and employee relationships are extremely important. “We are honored by the trust our investors
Celonis Unveils Platform Innovations to Power the AI-Driven, Composable Enterprise4.11.2025 11:00:00 CET | Press release
Celonis, a global leader in Process Intelligence, today at Celosphere 2025 announced major platform innovations that power enterprise AI to reinvent and continuously improve business operations. Daniel Brown, Chief Product Officer at Celonis, emphasized the need for a structured approach to agentic AI. “To truly operationalize AI, you need to identify the right use cases, redesign your business processes, and orchestrate the agents alongside your people and existing systems," Brown said. "Our enhanced capabilities empower our customers and their partners to build AI solutions that lift their operations to unprecedented levels of efficiency and agility.” The Celonis Process Intelligence Platform extracts raw data from systems, applications and devices within and across enterprises. It enriches this data with customers’ unique business context to create a living digital twin of operations—the Process Intelligence Graph. On top of the Graph, the Process Intelligence Platform provides the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom